Alumis (ALMS) Stock: Clinical Trial Results Send Shares Up 60% on Tuesday

TLDR Alumis stock jumped 60% after Phase 3 psoriasis drug trials showed 65% of patients hit PASI 90 and over 40% achieved complete skin clearance Envudeucitinib met all primary and secondary endpoints in two separate trials with high statistical significance The drug showed faster results than competitors, separating from placebo by Week 4 Baird raised [...]

The post Alumis (ALMS) Stock: Clinical Trial Results Send Shares Up 60% on Tuesday appeared first on Blockonomi.